정규장
로그인 회원가입
JNJ
Johnson & Johnson
7월 27일 10:43 AM ET (한국 7/27 23:43)
$263.40
+4.13 ▲ +1.59%

존슨앤드존슨(JNJ) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$634.1B
라지캡
P/E
30.5
적정 수준
배당수익률
2.04%
52주 위치
94%
저점 +60% · 고점 -2%
애널리스트
매수
B-
Fundamental health
vs. Drug Manufacturers - General
수익성 ⓘ
Top 38%
성장 ⓘ
Top 45%
밸류에이션 ⓘ
Top 11%
재무 안정 ⓘ
Top 66%
💰 Is this stock pricier than usual right now? ⓘ
Compared to this company's own recent 5년 (not other companies).
Very cheap
Cheap
Typical
Pricey
🔥 Very pricey
Simply put — what you pay today to own $1 of this company's yearly earnings is 30원. Over the past 5년, it usually traded around 23원. Earnings have also shrunk, which lifts the multiple — one of the priciest stretches of the past 5년.
Pricy doesn't mean bad — it means expectations are already baked in.
Index ⓘ DJIA, S&P 500P/E ⓘ 30.53EPS (ttm) ⓘ 8.63Insider Own ⓘ 0.14%Shs Outstand ⓘ 2.41BPerf Week ⓘ 4.09%
Market Cap ⓘ 634.06BForward P/E ⓘ 20.46EPS next Y ⓘ 10.2%Insider Trans ⓘ -9.96%Shs Float ⓘ 2.40BPerf Month ⓘ 9.29%
Enterprise Value ⓘ 662.34BPEG ⓘ 2.06EPS next Q ⓘ 3.05Inst Own ⓘ 76.19%Short Float ⓘ 1.11%Perf Quarter ⓘ 14.2%
Income ⓘ 21.04BP/S ⓘ 6.47EPS this Y ⓘ 8.28%Inst Trans ⓘ 0.32%Short Ratio ⓘ 3.24Perf Half Y ⓘ 20.55%
Sales ⓘ 97.94BP/B ⓘ 7.47EPS next 5Y ⓘ 9.95%ROA ⓘ 10.67%Short Interest ⓘ 26.58MPerf YTD ⓘ 27.28%
Book/sh ⓘ 35.28P/C ⓘ 30.55EPS past 3/5Y ⓘ 17.88% 14.9%ROE ⓘ 25.74%52W High ⓘ -2.24% ($269.43)Perf Year ⓘ 55.34%
Cash/sh ⓘ 8.62P/FCF ⓘ 28.5Sales past 3/5Y ⓘ 5.56% 2.67%ROIC ⓘ 17.72%52W Low ⓘ 60.38% ($164.23)Perf 3Y ⓘ 53.96%
Dividend Est. ⓘ $5.38 (2.04%)EV/EBITDA ⓘ 19.38EPS Y/Y TTM ⓘ -3.56%Gross Margin ⓘ 68.03%Volatility(W/M) ⓘ 2.08% 2.34%Perf 5Y ⓘ 53.33%
Dividend TTM ⓘ 5.24EV/Sales ⓘ 6.76Sales Y/Y TTM ⓘ 8.06%Oper. Margin ⓘ 26.99%ATR (14) ⓘ 5.96Perf 10Y ⓘ 110.67%
Dividend Ex-Date ⓘ 2026/8/25Quick Ratio ⓘ 0.81EPS Q/Q ⓘ -0.92%Profit Margin ⓘ 21.48%RSI (14) ⓘ 62.64Recom ⓘ 1.81
Dividend Gr. 3/5Y ⓘ 4.92% 5.25%Current Ratio ⓘ 1.09Sales Q/Q ⓘ 6.64%SMA20 ⓘ 2.7% ($256.48)Beta ⓘ 0.23Target Price ⓘ $275.81
Payout ⓘ 46.59%Debt/Eq ⓘ 0.58Earnings ⓘ 2026/7/15SMA50 ⓘ 8.87% ($241.94)Rel Volume ⓘ 0.77Prev Close ⓘ $259.27
Employees ⓘ 140800LT Debt/Eq ⓘ 0.44EPS/Sales Surpr. ⓘ 1.59% 0.99%SMA200 ⓘ 17.26% ($224.63)Avg Volume(3M) ⓘ 8.20MPrice ⓘ $263.4
IPO ⓘ 1944/9/25Option/Short ⓘ Yes/YesTrades ⓘ 101039Volume ⓘ 6,329,248Change ⓘ 1.59%
Quarterly earnings trend SEC filings · USD
24.9
24.12*
25.3
25.6
25.9
25.12*
26.3
26.6
Revenue Net income 최근 분기: 매출 $25.3B (YoY +7%) · 순이익 $5.5B (YoY 0%)
* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Johnson & Johnson (JNJ) Investment Analysis

What kind of company is Johnson & Johnson?

존슨앤드존슨(JNJ) 방어주
Healthcare · Drug Manufacturers - General
Top 23 by Market Cap — Global Large-Cap

💊 A global diversified healthcare company operating a two-pillar business structure of innovative pharmaceuticals and medtech (medical devices). Founded in 1886 in New Jersey, USA, it has expanded across the pharmaceuticals and medical devices sectors throughout its long history, and has established itself as a representative US dividend growth stock included in the Dow Jones Industrial Average.

Learn more about Johnson & Johnson →
Market Cap
$634B
Approx. KRW 869 trillion
⚖️ 2.2x Samsung Electronics
Market Cap Rank23
Employees140,800people
IPO1944/09/25
Current Price$263.40 ≈ 360,858원
📌 DJIA, S&P 500 · NYSE · USA

Key Events

⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date D-29
8월 25일 (화)
지급 6월 9일 (화)
💡 배당을 받으려면 8월 24일까지 매수하는게 좋습니다
📜 Recent events
🔔 Earnings release 2026년 7월 15일 (수) · 장 시작 전 EPS 1.75% 📈 매출 1.04%
🎯 Ex-div 2026년 5월 26일 (화) 주당 $1.34
🔔 Earnings release 2026년 4월 14일 (화) · 장 시작 전 EPS 1.12% 📈 매출 2.20%

Is it profitable?

Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
27.0%
✓ 평균
My positionMid-range
Low range Average High range
Drug Manufacturers - General Median 27.0% · Bottom 50%
💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수
Net Margin
Share of revenue left after taxes and interest are paid
21.5%
✓ 우수
My positionTop 25%
Low range Average High range
Drug Manufacturers - General Median 14.7% · Top 25%
💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
68.0%
✓ 평균
My positionMid-range
Low range Average High range
Drug Manufacturers - General Median 69.3% · Bottom 42%
💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)
ROE
Annual return earned on shareholders' equity (15%+ is strong)
25.7%
✓ 양호
My positionMid-range
Low range Average High range
Drug Manufacturers - General Median 25.7% · Around average
💡 일반적으로 15% 이상이면 우수 (단, 부채 레버리지 효과 주의)
ROA
Annual earnings relative to total company assets
10.7%
✓ 우수
My positionTop 25%
Low range Average High range
Drug Manufacturers - General Median 6.0% · Top 24%
💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수
ROIC
Return generated per dollar invested in the business
17.7%
✓ 우수
My positionTop 25%
Low range Average High range
Drug Manufacturers - General Median 7.9% · Top 21%
💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
0.58
✓ Healthy debt
My positionMid-range
Low range Average High range
Drug Manufacturers - General Median 0.94
💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)
Current Ratio
Liquid assets available to cover liabilities due within a year
1.09
✓ 평균
My positionMid-range
Low range Average High range
Drug Manufacturers - General Median 1.26
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
0.81
✓ 평균
My positionMid-range
Low range Average High range
Drug Manufacturers - General Median 1.01
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook
Positive and negative signals are mixed
애널리스트 목표가
$275.81
현재가 대비 +4.7%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
예상 PER (Forward)
20.46배
💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인
PEG (성장 반영 밸류)
2.06
고평가
💡 PEG > 2 — 성장 대비 비싼 편
내년 EPS 예상 성장률
+10.2%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
5년 EPS 예상 연평균
+9.9%
💡 장기 성장 전망. 15% 이상이면 고성장 기업
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Reliability
Beat estimates in 2 of the last 2 quarters
2
예상 상회
0
예상 부합
0
예상 하회
100%
상회 비율
+1.4%
평균 서프라이즈
2026.07.15
상회
실적 $2.90 · 예상 $2.85 +1.8%
2026.04.14
상회
실적 $2.70 · 예상 $2.67 +1.1%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth
Mid-range within the industry
Margin-Driven Growth EPS is growing while revenue is flat — gains may come from cost cuts, so watch sustainability
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
+8.3%
양호
My positionMid-range
Low range Average High range
Drug Manufacturers - General Median 2.3% · Top 35%
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
+10.2%
평균
My positionMid-range
Low range Average High range
Drug Manufacturers - General Median 11.7% · Bottom 44%
5-Year EPS CAGR Outlook
Projected average annual EPS growth over the next 5 years
+9.9%
양호
My positionMid-range
Low range Average High range
Drug Manufacturers - General Median 6.5% · Top 42%
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+17.9%
양호
My positionMid-range
Low range Average High range
Drug Manufacturers - General Median 5.5% · Top 35%
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
+14.9%
양호
My positionMid-range
Low range Average High range
Drug Manufacturers - General Median -1.4% · Top 30%
Past 5-Year Revenue
How much revenue grew over the past 5 years
+2.7%
평균
My positionMid-range
Low range Average High range
Drug Manufacturers - General Median 3.7% · Bottom 32%
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
+6.6%
평균
My positionMid-range
Low range Average High range
Drug Manufacturers - General Median 6.7% · Bottom 49%
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.
New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Underperformed the market by 15%p over 5 years
JNJ +53.3% · S&P 500 +68.0%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-14.6%p
behind the market
vs Health Care (XLV)
+29.7%p
ahead of the sector average
1-year basis
vs S&P 500
+38.9%p
well ahead of the market
vs Health Care (XLV)
+35.6%p
well ahead of the sector average
Current position within 52-week range
Low (-60.4%p) High (-2.2%p)
Current price is 60.4% above the 52-week low and 2.2% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-10.9%
Annualized volatility
21.0%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟢
Current diagnosis · 2026-07-24
Uptrend zone

Current price $263.40 above the midline ($256.48). Normal upward flow. Above the Ichimoku cloud (bullish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡
Current diagnosis · 2026-07-24
Neutral zone — weak trend

MACD 4.026 · Signal 4.341 · Hist -0.315. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🟢
Current diagnosis · 2026-07-24
Bullish zone

RSI 62.6 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 74.8.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Pricier than peers in its industry
Pricey on Vs. Earnings·Vs. Assets·Vs. Sales·Vs. Cash Flow
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
💵 Vs. Earnings Pricey
🏢 Vs. Assets Pricey
🧾 Vs. Sales Pricey
💧 Vs. Cash Flow Pricey
💵 Vs. Earnings
PER Price-to-Earnings Ratio
How expensive the price is vs. earnings — lower is cheaper
30.53x
✓ Pricey
My positionBottom 25%
Low range Average High range
Drug Manufacturers - General median 20.25x · Bottom 21% — expensive within the industry
💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)
💵 Vs. Earnings
Forward PER Forward Price-to-Earnings Ratio
PER using next year's estimated earnings — reflects growth
20.46x
✓ Very pricey
My positionBottom 5%
Low range Average High range
Drug Manufacturers - General median 13.52x · Bottom 1% — expensive within the industry
💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
7.47x
✓ Pricey
My positionBottom 25%
Low range Average High range
Drug Manufacturers - General median 6.32x · Bottom 25% — expensive within the industry
💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
6.47x
✓ Pricey
My positionBottom 25%
Low range Average High range
Drug Manufacturers - General median 3.17x · Bottom 13% — expensive within the industry
💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)
💧 Vs. Cash Flow
EV/EBITDA Enterprise Value Multiple
Total enterprise value ÷ operating cash earnings — a benchmark for M&A
19.38x
✓ Very pricey
My positionBottom 25%
Low range Average High range
Drug Manufacturers - General median 11.04x · Bottom 6% — expensive within the industry
💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)
💧 Vs. Cash Flow
P/FCF Price-to-Free-Cash-Flow Ratio
Price vs. actual cash generation — lower means more efficient
28.50x
✓ Very pricey
My positionBottom 5%
Low range Average High range
Drug Manufacturers - General median 15.70x · Bottom 3% — expensive within the industry
💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)
Analyst target price (reference)
$275.81 vs. current price +4.7%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Drug Manufacturers - General

Who owns it?

Ownership flow is positive
Insider modest net selling -10.0% · Institutional modest net buying +0.3% · Short interest light 1.1%
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
-10.0%
Insiders net selling
🏦 Institutions (funds & investors)
+0.3%
Institutions net buying
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 76.2%
Adequate institutional weight
Drug Manufacturers - General Median 62.4%
🧑‍💼 Insiders 0.1%
Low, common among large-caps
Drug Manufacturers - General Median 0.2%
👤 Retail investors (estimated) 23.7%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
1.1%
Low — limited short-side pressure
Drug Manufacturers - General Median 2.0%
Past 90 days Little change
Short interest days to cover
3.2 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 2.41B주
Float (tradable shares) 2.40B주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding JNJ

ETFs with the highest weightings · 10 total shown
IHE
IHE
iShares U.S. Pharmaceuticals ETF
23.03%
$1.6B
XLV
XLV
State Street Health Care Select Sector SPDR ETF
11.10%
$41.7B
IYH
IYH
iShares U.S. Healthcare ETF
10.14%
$3.3B
FHLC
FHLC
Fidelity MSCI Health Care Index ETF
8.94%
$3.3B
VHT
VHT
Vanguard Health Care ETF
8.74%
$18.2B
* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

배당 지급 — 연 2.04%
배당보다 주가 성장에 가까운 비중
Dividend Yield
2.04%
Industry average 1.25%
Dividend Per Share
$5.38
Annualized
Payout Ratio
47%
Share of net income paid as dividends
5-Year Growth
5.3%
Annualized dividend growth
🏆 55년 연속 배당 증가
📅 지급월 2월 · 8월 · 11월
📊 총 이력 1970~2026 (225건)
연도별 배당 총액 추이
주당 배당금을 연 단위로 합산한 금액입니다. 막대가 우상향이면 매년 배당이 늘어나고 있다는 뜻입니다.
$3.15 +6.8%
2016
$3.32 +5.4%
2017
$3.54 +6.6%
2018
$3.75 +5.9%
2019
$3.98 +6.1%
2020
$4.19 +5.3%
2021
$4.45 +6.2%
2022
$4.70 +5.6%
2023
$4.91 +4.5%
2024
$5.14 +4.7%
2025
$X.XX 그 해 총 배당금 +X% 전년 대비 증가 -X% 감소
최근 배당 이력 총 225건
아래로 스크롤하면 과거 배당 이력을 볼 수 있습니다.
배당락일
주당 금액
지급일
당시 수익률
2026-02-24
$1.30
—
2.11%
2025-11-25
$1.30
—
3.09%
2025-08-26
$1.30
—
3.58%
2025-05-27
$1.30
—
3.28%
2025-02-18
$1.24
—
3.20%
2024-11-26
$1.24
—
3.18%
2024-08-27
$1.24
—
2.98%
2024-05-20
$1.24
—
3.97%
2024-02-16
$1.19
—
3.76%
2023-11-20
$1.19
—
3.89%
2023-08-25
$1.19
—
2.79%
2023-05-22
$1.19
—
3.64%
2023-02-17
$1.13
—
3.48%
2022-11-21
$1.13
—
3.13%
2022-08-22
$1.13
—
3.25%
2022-05-23
$1.13
—
2.99%
2022-02-18
$1.06
—
3.21%
2021-11-22
$1.06
—
3.26%
2021-08-23
$1.06
—
2.90%
2021-05-24
$1.06
—
2.40%
2021-02-22
$1.01
—
3.08%
2020-11-23
$1.01
—
3.43%
2020-08-24
$1.01
—
3.20%
2020-05-22
$1.01
—
3.33%
2020-02-24
$0.950
—
3.22%
2019-11-25
$0.950
—
3.39%
2019-08-26
$0.950
—
3.60%
2019-05-24
$0.950
—
3.28%
2019-02-25
$0.900
—
3.26%
2018-11-26
$0.900
—
3.10%
2018-08-27
$0.900
—
2.58%
2018-05-25
$0.900
—
3.51%
2018-02-26
$0.840
—
2.54%
2017-11-27
$0.840
—
2.40%
2017-08-25
$0.840
—
2.49%
2017-05-25
$0.840
—
2.54%
2017-02-24
$0.800
—
2.61%
2016-11-18
$0.800
—
3.38%
2016-08-19
$0.800
—
3.21%
2016-05-20
$0.800
—
3.37%
2016-02-19
$0.750
—
3.55%
2015-11-20
$0.750
—
3.56%
2015-08-21
$0.750
—
3.77%
2015-05-21
$0.750
—
3.47%
2015-02-20
$0.700
—
3.45%
2014-11-21
$0.700
—
3.17%
2014-08-22
$0.700
—
3.28%
2014-05-22
$0.700
—
3.31%
2014-02-21
$0.660
—
3.55%
2013-11-22
$0.660
—
3.36%
2013-08-23
$0.660
—
3.56%
2013-05-23
$0.660
—
3.55%
2013-02-22
$0.610
—
3.95%
2012-11-23
$0.610
—
4.27%
2012-08-24
$0.610
—
4.33%
2012-05-24
$0.610
—
4.58%
2012-02-24
$0.570
—
4.37%
2011-11-25
$0.570
—
4.55%
2011-08-26
$0.570
—
4.29%
2011-05-26
$0.570
—
4.17%
2011-02-25
$0.540
—
3.62%
2010-11-26
$0.540
—
3.39%
2010-08-27
$0.540
—
3.58%
2010-05-27
$0.540
—
3.41%
2010-02-19
$0.490
—
3.79%
2009-11-20
$0.490
—
3.84%
2009-08-21
$0.490
—
3.87%
2009-05-21
$0.490
—
4.24%
2009-02-20
$0.460
—
4.13%
2008-11-21
$0.460
—
3.79%
2008-08-22
$0.460
—
3.03%
2008-05-22
$0.460
—
3.24%
2008-02-22
$0.415
—
3.22%
2007-11-23
$0.415
—
2.98%
2007-08-24
$0.415
—
3.16%
2007-05-24
$0.415
—
3.02%
2007-02-23
$0.375
—
2.85%
2006-11-24
$0.375
—
2.21%
2006-08-25
$0.375
—
2.18%
2006-05-25
$0.375
—
2.26%
2006-02-24
$0.330
—
2.29%
2005-11-18
$0.330
—
2.04%
2005-08-19
$0.330
—
1.93%
2005-05-13
$0.330
—
2.19%
2005-02-11
$0.285
—
2.07%
2004-11-12
$0.285
—
2.19%
2004-08-13
$0.285
—
2.32%
2004-05-14
$0.285
—
2.28%
2004-02-12
$0.240
—
2.13%
2003-11-14
$0.240
—
2.17%
2003-08-15
$0.240
—
2.14%
2003-05-16
$0.240
—
1.89%
2003-02-13
$0.205
—
1.95%
2002-11-15
$0.205
—
1.62%
2002-08-16
$0.205
—
1.72%
2002-05-17
$0.205
—
1.50%
2002-02-14
$0.180
—
1.54%
2001-11-16
$0.180
—
1.44%
2001-08-17
$0.180
—
1.56%
2001-05-18
$0.180
—
1.62%
2001-02-15
$0.160
—
1.36%
2000-11-17
$0.160
—
1.30%
2000-08-18
$0.160
—
1.24%
2000-05-19
$0.160
—
1.31%
2000-02-11
$0.140
—
1.77%
1999-11-12
$0.140
—
1.29%
1999-08-13
$0.140
—
1.35%
1999-05-14
$0.140
—
1.38%
1999-02-11
$0.125
—
1.44%
1998-11-13
$0.125
—
1.41%
1998-08-14
$0.125
—
1.55%
1998-05-15
$0.125
—
1.61%
1998-02-12
$0.110
—
1.54%
1997-11-14
$0.110
—
1.67%
1997-08-15
$0.110
—
1.80%
1997-05-16
$0.110
—
1.63%
1997-02-13
$0.095
—
1.50%
1996-11-15
$0.095
—
1.45%
1996-08-16
$0.095
—
1.38%
1996-05-17
$0.095
—
1.44%
1996-02-15
$0.083
—
1.39%
1995-11-10
$0.083
—
1.61%
1995-08-11
$0.083
—
1.81%
1995-05-10
$0.083
—
2.24%
1995-02-08
$0.072
—
2.47%
1994-11-08
$0.072
—
2.55%
1994-08-10
$0.072
—
2.80%
1994-05-11
$0.072
—
3.14%
1994-02-09
$0.065
—
3.05%
1993-11-09
$0.065
—
2.89%
1993-08-11
$0.065
—
3.40%
1993-05-12
$0.065
—
2.71%
1993-02-09
$0.058
—
2.51%
1992-11-10
$0.058
—
2.21%
1992-08-12
$0.058
—
2.18%
1992-05-13
$0.058
—
2.17%
1992-02-11
$0.050
—
1.86%
1991-11-13
$0.050
—
1.92%
1991-08-14
$0.050
—
2.00%
1991-05-15
$0.050
—
1.93%
1991-02-12
$0.043
—
2.10%
1990-11-14
$0.043
—
2.42%
1990-08-15
$0.043
—
2.27%
1990-05-16
$0.043
—
2.46%
1990-02-13
$0.036
—
2.56%
1989-11-15
$0.036
—
2.44%
1989-08-16
$0.036
—
2.61%
1989-05-22
$0.036
—
2.02%
1989-02-14
$0.031
—
2.73%
1988-11-16
$0.031
—
2.37%
1988-08-17
$0.031
—
2.29%
1988-05-18
$0.031
—
3.14%
1988-02-17
$0.026
—
2.51%
1987-11-16
$0.026
—
2.51%
1987-08-17
$0.026
—
1.86%
1987-05-22
$0.026
—
2.19%
1987-02-23
$0.022
—
2.08%
1986-11-17
$0.022
—
2.51%
1986-08-18
$0.022
—
2.33%
1986-05-23
$0.022
—
2.38%
1986-02-24
$0.020
—
2.61%
1985-11-18
$0.020
—
2.55%
1985-08-19
$0.020
—
3.38%
1985-05-24
$0.020
—
2.61%
1985-02-15
$0.019
—
3.83%
1984-11-16
$0.019
—
3.48%
1984-08-20
$0.019
—
3.48%
1984-05-21
$0.019
—
3.36%
1984-02-17
$0.017
—
3.84%
1983-11-14
$0.017
—
2.99%
1983-08-15
$0.017
—
2.95%
1983-05-16
$0.017
—
2.62%
1983-02-18
$0.016
—
2.64%
1982-11-15
$0.016
—
2.66%
1982-08-16
$0.016
—
3.03%
1982-05-17
$0.016
—
2.80%
1982-02-22
$0.014
—
2.35%
1981-11-16
$0.014
—
3.06%
1981-08-17
$0.014
—
3.30%
1981-05-22
$0.014
—
2.18%
1981-02-13
$0.012
—
2.98%
1980-11-17
$0.012
—
2.50%
1980-08-18
$0.012
—
3.30%
1980-05-19
$0.012
—
3.29%
1980-02-15
$0.010
—
3.45%
1979-11-16
$0.010
—
2.86%
1979-08-20
$0.010
—
2.52%
1979-05-21
$0.010
—
2.65%
1979-02-20
$0.010
—
2.49%
1978-11-13
$0.009
—
2.73%
1978-08-14
$0.009
—
2.30%
1978-05-15
$0.009
—
2.43%
1978-02-10
$0.009
—
2.60%
1977-11-14
$0.007
—
2.24%
1977-08-15
$0.007
—
2.21%
1977-05-16
$0.007
—
2.23%
1977-02-18
$0.007
—
1.67%
1976-11-15
$0.005
—
1.54%
1976-08-16
$0.005
—
1.40%
1976-05-17
$0.005
—
1.35%
1976-02-13
$0.006
—
1.24%
1975-11-17
$0.004
—
1.13%
1975-08-18
$0.004
—
1.25%
1975-05-19
$0.004
—
1.05%
1975-02-14
$0.005
—
1.07%
1974-11-18
$0.004
—
0.88%
1974-08-19
$0.004
—
0.91%
1974-05-20
$0.003
—
0.62%
1974-02-15
$0.004
—
0.68%
1973-11-16
$0.003
—
0.52%
1973-08-20
$0.003
—
0.53%
1973-05-21
$0.003
—
0.51%
1973-02-16
$0.003
—
0.48%
1972-11-17
$0.002
—
0.43%
1972-08-21
$0.002
—
0.44%
1972-05-22
$0.002
—
0.37%
1972-02-18
$0.003
—
0.54%
1971-11-19
$0.002
—
0.48%
1971-08-23
$0.002
—
0.43%
1971-05-17
$0.002
—
0.54%
1971-02-22
$0.003
—
0.55%
1970-11-16
$0.002
—
0.61%
1970-08-17
$0.002
—
0.60%
1970-05-22
$0.002
—
0.43%
1970-02-16
$0.002
—
0.19%
* "배당락일"은 배당받으려면 이 날 이전에 주식을 보유해야 하는 기준일입니다. 지급일·당시 수익률은 일부 종목에서 데이터가 없을 수 있습니다.
💰 내가 100만원 투자한다면
연간 배당금 (세후) 1.7만원
5년 누적 (세후) 9.6만원
* 환율 1,370원, 세금 15% 반영. 5년 누적은 배당 성장률 연 5.25% 가정.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
JNJ This Stock
$634.1B30.5 ▼7.5 ▼25.74% ▲2.04% ▲+1.6%
LLY
$1.13T43.0 ▼36.2 ▼107.64% ▲0.58% ▼+0.9%
ABBV
$458.2B127.9 ▼- 15221.82% ▲2.65% ▲+0.9%
UNH
$382.1B27.1 ▼3.9 ▼12.49% ▲2.15% ▲-0.7%
MRK
$323.7B36.9 ▼7.1 ▼18.97% ▲2.49% ▲+0.5%
NVS
$283.8B23.4 ▲6.8 ▼30.56% ▲2.87% ▲-0.7%
Sector Avg-25.82.7-48.83%1.25%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen
→

Related News & Content

📖 Company overview
존슨앤드존슨(JNJ) 뭐하는 회사일까? - 주가 전망·실적·시총·관련주·본사 총정리
존슨앤드존슨(JNJ)은 혁신 의약품·의료기기 두 축의 글로벌 종합 헬스케어 기업입니다. 안정적인 매출 흐름과 오랜 연속 배당 성장 정책, 사업 다각화 구조와 견조한 잉여현금흐름이 특징이며 본사는 미국에 위치한 대표 헬스케어 종목입니다.
💼 Recent Earnings Analysis
존슨앤드존슨($JNJ) 2026년 2분기 실적 분석 — 매출·이익 모두 예상 상회, 연간 가이던스 상향
존슨앤드존슨($JNJ)이 2026년 2분기에 매출과 이익 모두 시장 예상을 웃돌았습니다. 매출은 전년 동기 대비 6.6% 늘어난 253억 달러로 예상치(약 250억 5천만 달러)를 넘었고, 조정 주당순이익(EPS)은 2.90달러로 컨센서스 2.85달러와 지난해 2.77달러를 모두 상회했습니다. 회사는 연간 매출 전망을 1,011억 달러(중간값 기준 7.3% 성장)로, 조정 EPS 전망은 0.13달러 올린 11.68달러로 상향했습니다. 실적이 장 시작 전 발표돼 정규장 반응은 확인 전이나, 발표 전 주가는 사상 최고가 부근에서 강세를 보였습니다.
존슨앤드존슨(JNJ) 2026년 1분기 실적 분석 — 스텔라라 절벽 넘고 가이던스 상향
존슨앤드존슨은 1분기 조정 EPS $2.70(예상 $2.66~2.68), 매출 $241억(예상 $236억)으로 모두 상회하며 연간 가이던스를 상향 조정했습니다. 스텔라라가 바이오시밀러에 62% 급감했지만, 다잘렉스 $40억 돌파(+18%)와 트렘피아 +64% 성장이 이를 상쇄했습니다. 메드테크도 +7.7%로 견조하며, 배당을 3.1% 인상해 64년 연속 인상 기록을 이어갔습니다.
📚 Related Investment Guides
2026년 미국 배당귀족(Dividend Aristocrats) 완전 가이드
S&P 500 소속, 25년 이상 연속 배당 인상한 배당귀족주 69개 전체 리스트. 섹터별 분포, 배당수익률 순위, NOBL ETF 비교까지 한눈에.
미국주식 세금 총정리 2026 — 초보자를 위한 계산법과 절세 전략
2026년 미국주식 세금 총정리. 양도소득세 22% 계산법, 배당세 15% 원천징수, 손익통산, 절세 전략까지. 실제 금액 시뮬레이션과 세금 계산기로 내 세금을 직접 확인해보세요.

FAQ

What kind of company is 존슨앤드존슨(JNJ)?

존슨앤드존슨(JNJ) belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.

What is the market cap of JNJ?

The market cap of JNJ is approximately $634.1B, ranking 23 within its sector.

Does JNJ pay dividends?

JNJ has a dividend yield of approximately 2.04%, with an annual dividend of $5.38.

What is the P/E ratio of JNJ?

JNJ has a P/E ratio of approximately 30.5x, which can be used to assess its valuation relative to the Healthcare sector average.

What is the 52-week high and low for JNJ?

JNJ has recorded a 52-week high of $269.43 and a low of $164.23.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.